Cardiac drugs and outcome in COVID-19

Ajay Kumar Mishra
Saint Vincent Hospital

Let us know how access to this document benefits you.
Follow this and additional works at: https://escholarship.umassmed.edu/covid19

Part of the Cardiology Commons, Cardiovascular Diseases Commons, Infectious Disease Commons, and the Virus Diseases Commons

Repository Citation

This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Coronavirus COVID-19 Publications by UMMS Authors by an authorized administrator of eScholarship@UMMS. For more information, please contact Lisa.Palmer@umassmed.edu.
Title page

Type of article: Letter to Editor

Title: Cardiac drugs and outcome in COVID - 19

Ajay Kumar Mishra*MD, Kamal Kant Sahu*MD, Jennifer Sargent**DO

Corresponding author,
Dr. Ajay Kumar Mishra, MD
Department of Internal Medicine
Saint Vincent Hospital
Worcester, Massachusetts
USA, 01608
Ajay.Mishra@stvincenthospital.com
Phone: 5083635000
Word count: 466
Number of Pages: 3

* Postgraduate in Internal Medicine, Saint Vincent Hospital, Worcester, Massachusetts
** Assistant Professor in Internal Medicine, University of Massachusetts Medical School, Saint Vincent Hospital, Worcester, Massachusetts

© The Author(s) 2020. Published by Oxford University Press on behalf of the Association of Physicians. All rights reserved. For Permissions, please email: journals.permissions@oup.com

https://mc.manuscriptcentral.com/qjm
2. Kamal Kant Sahu, MD
Department of Internal Medicine
Saint Vincent Hospital
Worcester, Massachusetts
USA, 01608
kamalkant.sahu@stvincenthospital.com

3. Jennifer Sargent, DO, FACP
Department of Internal Medicine,
Saint Vincent Hospital, and
University of Massachusetts Medical School
Worcester, Massachusetts
USA, 01608
Jennifer.Sargent@stvincenthospital.com
04162282500

CONFLICT OF INTEREST: Authors have no conflicts of interest to declare.

ETHICAL STATEMENT: The article doesn’t contain the participation of any human
being and animal.

VERIFICATION: All authors have seen the manuscript and agree to the content and
data. All the authors played a significant role in the paper.

Patient consent: Not applicable
We read with much interest the article “Are certain drugs associated with enhanced mortality in COVID -19” by Goldstein et al your esteemed Journal. Authors have discussed the theoretical basis of angiotensin receptor blockers, statins in worsening outcome of COVID –19 patients. We believe that this topic is rapidly evolving and requires further evidence and discussion for understanding the multiple factors which contribute to the pathogenesis and outcome. We have the following comments.

Goldstein et al. have discussed that ARB’s facilitate viral entry by increasing the expression of ACE 2 receptors resulting in greater disease severity. Cao et al have compared the genetic analysis of COVID -19 receptor ACE -2 in different populations. They have shown that the expression level and pattern of ACE-2 receptors is different in different tissue and different populations. Even though they have shown that the East Asian population has a higher expression of the same, surprisingly reported mortality in this population has not been high compared to certain other countries.

Zheng et al have reported that patients with cardiovascular diseases have increased ACE- 2 as compared to individuals. As it is expressed in the heart and is involved in counteracting the effects of angiotensin II, its levels are elevated in hypertension, congestive heart failure, atherosclerosis, coronary artery disease due to activation of training angiotensin system. They also have mentioned that renin – angiotensin- aldosterone system inhibitors can also increase ACE-2 levels, hence any antihypertensive agent including ARBs, ACE inhibitors could possibly worsen the outcome in patients with COVID -19. In animal models Administration of aldosterone has also shown to downregulate ACE 2 mRNA levels. Hence
possibly its antagonists could also increase ACE-2 levels.(5) Similarly, in the animal model binding of SARS-CoV spike protein to ACE 2 has been soon to cause downregulation of ACE 2, resulting in an increase in angiotensin II and worsening lung injury. Recombinant ACE 2 and Losartan is shown to reduce lung injury in such case. (6) Surprisingly randomized controlled trials of losartan for patients with COVID -19 are being held in both hospitalized and non-hospitalized patients. (6,7)

We agree with the authors that increase expression of ACE 2 receptor potentially increases viral entry and disease severity, however the data regarding only ARB’s causing the same might not be enough.(6,8) While awaiting further studies it would be prudent to discontinue ACE inhibitors, ARB’s, and other RAAS antagonist on clinical ground as per the treating physician’s discretion.(9)

Though at present there is not enough evidence of any potential benefit or harm of most prescribed medications including the ARBs, ACEi, Statins, Antiviral agents we strongly agree with the authors that meticulous and detailed reporting of medications of COVID -19 affected patients is crucial in order to further understand the multifaceted interaction of the virus, medications, and clinical outcome.

References:


